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Background: Visceral leishmaniasis (VL) is a serious public health challenge in Brazil and dogs are considered to be
the main urban reservoir of the causative agent. The culling of animals to control VL in some countries makes the
accurate diagnosis of canine VL (CVL) essential. Recombinant antigens rLci1A and rLci2B were selected from a cDNA
library of Leishmania infantum amastigotes due to their strong potential as candidates in diagnostic testing for CVL.
The present multicentric study aimed to evaluate the sensitivity of a prototype test using these antigens (DPP
rLci1A/rLci2B) against 154 sera obtained from symptomatic dogs within three endemic areas of VL in Brazil. The
specificity was evaluated using 40 serum samples from negative dogs and dogs infected with other pathogens.
Sensitivity and specificity rates of DPP rLci1A/rLci2B prototype were compared to rates from other diagnostic tests
currently in use by the Brazilian Ministry of Health, including DPP®LVC, EIE®LVC.
Findings: DPP rLci1A/rLci2B prototype offered similar performance to that offered by DPP®LVC rapid test, as
follows: sensitivity of 87% (CI 81–91) and 88% (CI 82–93) and specificity of 100% (CI 91–100) and 97% (CI 87–100),
respectively for DPP rLci1A/rLci2B and DPP®LVC. When results of these two tests were considered concomitantly,
sensitivity increased to 93.5% (CI 89–96).
Conclusions: The recombinant antigens rLci1A and rLci2B represent promising candidates for use in a multi-antigen
rapid test for CVL. The inclusion of novel antigens to the DPP rLci1A/rLci2B prototype model could offer additionally
enhanced sensitivity to detect animals infected by L. infantum.
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Visceral leishmaniasis (VL) is caused by infection with
Leishmania infantum and dogs are considered to be the
main urban reservoir. Some countries advocate the culling
of dogs infected with L. infantum [1] as a control measure
for VL, making accurate diagnosis crucial in order to* Correspondence: pveras@bahia.fiocruz.com
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Until December 2011, the Brazilian Ministry of Health
recommended the use of enzyme-linked immunosorbent
assays (ELISA) and indirect immunofluorescence assays
(IFA) to diagnose L. infantum infection in dogs [4]. Unfor-
tunately, these immunological assays, offer moderate
sensitivity and specificity, thereby contributing to the
maintenance of infected animals in endemic areas [5,6].
An immunochromatographic rapid test (DPP®LVC) based
on the rK28 has recently become the preferred diagnostic
method for screening in Brazil, followed by ELISAtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
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strated 98% sensitivity using DPP®LVC in symptomatic
dogs, yet found low sensitivity (47%) in asymptomatic
dogs [7]. Putting the use of this protocol for canine
visceral leishmaniasis (CVL) diagnosis under scrutiny.
For improving VL control measures, the identification of
novel recombinant antigens may contribute to enhance
test sensitivity.
The antigens used in the prototype test evaluated in
this study, rLci1A and rLci2B, were selected from a
cDNA library of L. infantum amastigotes due to their
reactivity to antibodies from naturally infected dogs [8].
A previous study demonstrated that rLci1A and rLci2B
offer 96% and 100% sensitivity, with respective specificity
rates of 92% and 95% under ELISA against sera from
animals with positive parasitological test results [9]. These
findings clearly indicate the potential of these selected
antigens for use in CVL diagnosis.
The present study aimed to evaluate the sensitivity of
antigens rLci1A and rLci2B impregnated in an immu-
nochromatographic rapid test prototype based on the
dual path platform—DPP (hereafter referred to as DPP
rLci1A/rLci2B) for the serodiagnosis of dogs infected
by L. infantum in three endemic areas of VL. Moreover,
test sensitivity and specificity was compared to the
DPP®LVC and EIE®LVC tests, which are actively used to
diagnose CVL in endemic regions of Brazil.
Methods
Study design
The present multicentric study aimed to evaluate the
performance offered by the DPP rLci1A/rLci2B proto-
type test for the serodiagnosis of CVL. A total of 154
serum samples were obtained from naturally infected
symptomatic dogs in three endemic areas of Brazil, which
presented evidence of active L. infantum infection in
culture. The included sera were provided by the serum
banks of three laboratories of The National Institute of
Science and Technology in Tropical Diseases (INCT-DT),
located in Salvador–Bahia (BA) (n = 53), Natal–Rio Grande
do Norte (RN) (n = 50) and Ouro Preto–Minas Gerais
(MG) (n = 51). Animal population from RN is formed by
domiciled dogs, from MG by stray dogs and from BA by
both domiciled and stray dogs. All of 154 dogs presented
more than 3 signs at clinical examination. L. infantum
infection was identified using multilocus enzyme electro-
phoresis of parasites isolated from cultures of splenic
aspirates taken from dogs from RN and BA, and using
PCR-RFLP of parasites isolated from cultures of splenic
or bone marrow aspirates from dogs from MG. A total
of 40 serum samples, 20 from negative dogs, 5 infected
by Leishmania braziliensis, 5 by Trypanosoma cruzi, 6
by Ehrlichia canis and 4 by Babesia canis, selected
from a serum bank located in BA, were used toevaluate the specificity offered by the tests evaluated:
DPP®LVC, EIE®LVC and DPP rLci1A/rLci2B prototype test.
Antigen production and purification
Escherichia coli BL21(DE3)pLysS (Invitrogen) were trans-
formed with pRSET plasmids (Invitrogen) containing the
Lci1A or Lci2B L. infantum gene insert. Affinity chroma-
tography was used to purify the rLci1A and rLci2B proteins
as previously described [9].
Prototype production
The DPP rLci1A/rLci2B prototype test employed rLci1A
and rLci2B antigens impregnated on nitrocellulose mem-
brane strips in individual bands. This prototype utilizes
the same platform as the DPP®LVC (Biomanguinhos).
Two prototype models were produced, each with dif-
ferent concentrations of the two antigens: 1) rLci1A and
rLci2B at 0.35 mg/mL and 0.20 mg/mL; 2) rLci1A and
rLci2B at 0.70 mg/mL and 0.70 mg/mL.
Diagnostic test procedures
Each of the three included INCT-DT laboratories con-
ducted DPP rLci1A/rLci2B prototype diagnostic test proce-
dures in accordance with manufacturer recommendations
(BioManguinhos/FIOCRUZ) and the visual result was
interpreted. If a band was visible in the test area, likewise
in the control area, the result was considered positive.
When no bands were visible in the test area, but one was
present in the control area, a negative result was recorded.
All other band combinations were disregarded.
Analysis of prototype test results
Sensitivity and specificity rates were calculated with 95%
confidence interval. Sensitivity and specificity rates of the
DPP®LVC and EIE®LVC tests were compared to sensitivity
of the DPP rLci1A/rLci2B prototype. Kappa index [10]
was calculated by STATA program (StataCorp LP, College
Station, Texas, USA) as an agreement measure among
tests with respect to a given sample. Fisher’s exact test was
used to identify differences among positivity rates from
diagnostic tests using GraphPad Prism software (Graph
Pad, San Diego, California, USA). p value less than 0.05
was considered significant.
Ethical considerations
All serological sample obtainment procedures employed
were submitted for approval by the Institutional Review
Board for Animal Research at the Gonçalo Moniz Research
Center in Salvador, Bahia, in addition to the institutional
review boards of the other included centers.
Results and discussion
DPP®LVC and EIE®LVC test sensitivity remained largely
consistent among centers (Table 1), with no statistically
Table 1 Comparison of diagnostic test sensitivity
Serum sample Comparison of diagnostic test sensitivity (95% CI) [n/N]
Source EIE®LVC DPP® LVC DPP rLci1A DPP rLci2B DPP rLci1A/rLci2B DPP® LVC + DPPrLci1A/rLci2B
BA 98% 92.5% 66% 81.1% 83% 96.2%
(86–100) (82–97) (53–77) (69–89) (71–91) (87–99)
[49/50] [49/53] [35/53] [43/53] [44/53] [51/53]
MG 93.5% 84% 70% 76% 84% 88%
(92–100) (72–92) (56–81) (63–86) (72–92) (76–94)
[43/46] [42/50] [35/50] [38/50] [42/50] [44/50]
RN 100% 88.2% 90.2% 90.2% 94.1% 96%
(93–100) (77–95) (79–96) (79–96) (84–98) (87–99)
[51/51] [45/51] [46/51] [46/51] [48/51] [49/51]
Total* 97.3% 88.3% 75.3% 82.5% 87% 93.5%
(93–99) (82–93) (68–82) (76–88) (81–91) (89–96)
[143/147**] [136/154] [116/154] [127/154] [134/154] [144/154]
Abbreviations: CI = confidence interval, n = number of sera that tested positive, N = number of sera evaluated.
*154 canine serum samples tested positive for VL in culture and were obtained from three participating INCT-DT laboratories.
**7 out of 154 canine serum samples were not considered under ELISA due to inconclusive test results.
Figure 1 Positivity rates of DPP rLci1A / rLci2B regarding detection
of serum samples from L. infantum-infected dogs. The antigens
rLci1A / rLci2B were individually impregnated at concentrations of
0.35/0.20 mg/mL and 0.70/0.70 mg/mL, respectively. Positivity rates for
either proteins were analyzed both individually and collectively. A total
of 154 canine serum samples were obtained from the three INCT-DT
laboratories included in this study.
Fraga et al. Parasites & Vectors 2014, 7:136 Page 3 of 5
http://www.parasitesandvectors.com/content/7/1/136significant differences detected. DPP®LVC provided 92.5%
sensitivity in sera from Bahia (BA), 84% in sera from
Minas Gerais (MG) and 88.2% in samples from Rio
Grande do Norte (RN). The EIE®LVC test offered the
highest sensitivity of all the techniques evaluated, with
98% in sera from BA, 93.5% in samples from MG and
100% in sera from RN.
To evaluate the sensitivity of the DPP rLci1A/rLci2B
prototype, the 154 canine sera included were initially
analyzed by considering reactivity to each recombinant
antigen separately. Under lower antigen concentrations,
rLci1A (0.35 mg/mL) was detected in 32% of the sera
from BA, 14% from MG and 29% from RN. Notably, at
the higher concentration (0.70 mg/mL), rLci1A sensitivity
increased to 66%, 70% and 90%, respectively. Similarly,
when rLci2B was impregnated at a lower concentration
(0.20 mg/mL), only 60% of the sera from BA, 50% from
MG and 65% from RN tested positive. However, at the
higher concentration of 0.70 mg/mL, rLci2B sensitivity
increased considerably to 81%, 76% and 90%, respectively
(Figure 1, Table 1).
Next, the global test results of the DPP rLci1A/rLci2B
prototype model were evaluated by considering the
resulting sensitivity when at least one of the two proteins
evaluated were detected by antibodies in serum samples
at higher concentrations (0.70 mg/mL). The observed
sensitivity of the dual-antigen prototype test increased
considerably, with 83% of the sera from BA, 84% from
MG and 94% from RN presenting reactivity to at least
one of the two antigens present in the prototype test
(Table 1). The corresponding Kappa index value of 0.5162
indicated moderate agreement with respect to rLci1A and
rLci2B recognition among the 154 samples, suggesting
Table 2 Comparison of diagnostic test specificity
Serum sample Comparison of diagnostic test specificity (CI) [n/N]
EIE®LVC DPP® LVC DPP rLci1A DPP rLci2B DPP rLci1A/rLci2B
L. braziliensis 25% 100% 100% 100% 100%
(5–70) (57–100) (57–100) (57–100) (57–100)
[3/4] [0/5] [0/5] [0/5] [0/5]
T. cruzi 50% 100% 100% 100% 100%
(15–85) (57–100) (57–100) (57–100) (57–100)
[2/4] [0/5] [0/5] [0/5] [0/5]
E. canis 67% 100% 100% 100% 100%
(30–90) (61–100) (61–100) (61–100) (61–100)
[2/6] [0/6] [0/6] [0/6] [0/6]
B. canis 50% 100% 100% 100% 100%
(15–85) (51–100) (51–100) (51–100) (51–100)
[2/4] [0/4] [0/4] [0/4] [0/4]
Negative dogs 88% 95% 100% 100% 100%
(66–97) (76–99) (84–100) (84-100 (84–100)
[2/17] [1/20] [0/20] [0/20] [0/20]
Total 26% 97.5% 100% 100% 100%
(14–42) (87–100) (91–100) (91–100) (91–100)
[26/35] [1/40] [0/40] [0/40] [0/40]
Abbreviations: C = confidence interval, n = number of sera that tested positive, N = number of sera evaluated.
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prototype.
The DPP®LVC and DPP rLci1A/rLci2B tests exhibited
remarkably similar rates of sensitivity: 88% and 87%,
respectively. Agreement between these two DPP test
formats was moderate, with a Kappa index value of
0.459 (P < 0.001).
A lack of agreement was observed in 18 out of 154
sera when comparing DPP®LVC and DPP rLci1A/rLci2B
results. Ten samples tested positive under DPP®LVC and
negative using the DPP rLci1A/rLci2B prototype, while
eight were negative under DPP®LVC yet positive using
the prototype.
Since sera from asymptomatic dogs were not included
in the present report, the accuracy rates obtained herein
may be overestimated.
The specificity of the tests is shown in Table 2. Briefly,
the observed specificity values were 97% for DPP® LVC
and 100% for the DPP rLci1A/rLci2B prototype, values
that were much higher than that for EIE®LVC (26%). It is
noteworthy that EIE®LVC offered the highest sensitivity
rate among all techniques evaluated, although it presented
the lowest specificity value.
Taken together, the results presented herein demonstrate
that a multi-antigen DPP test format would enhance
sensitivity, as evidenced by an up to 5% increase in test
sensitivity using a prototype model employing three
antigens. The findings herein are further supported byprevious studies utilizing recombinant antigens from dif-
ferent pathogens, which found similarly favourable results
[11-14]. The rationale for using more than one recombin-
ant antigen is based on a study by Teixeira et al. [15], who
demonstrated that the concomitant use of recombinant
antigens can increase diagnostic test sensitivity. This find-
ing can be explained by the production of a unique set of
antibodies against a specific set of parasite antigens by
each individual who becomes infected with Leishmania.
In conclusion, rLci1A and rLci2B represent promising
candidates for inclusion in a future version of the DPP
rapid test for the serodiagnosis of CVL. Preliminary results
indicate that by combining these two antigens together
with the existing rK28 antigen DPP®LVC rapid test cur-
rently in use, sensitivity would increase from 88% to
93.5%. Further investigation is warranted to compre-
hensively determine the efficacy of a multi-antigen test
in field applications.
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